Dispensaries Can Boost Cannabis Sales with Unique Topical Products
June 7th, 2021
App, Exclusive, News, Top Story
As the legal cannabis industry matures and expands, the goal of many companies is (and should be) to reach people who might not historically be cannabis consumers. According to a 2020 Gallup poll, about 12% of US adults say they smoke marijuana. This percentage has remained fairly steady over the past several years, even in the face of widespread legalization. In order to reach a much wider market, the industry clearly needs options that don’t involve smoking.
Enter cannabis-derived products, such as tinctures, creams, and edibles. People who don’t like the idea of smoking may well be inclined to try some of these alternate products. Add in the recent boom in CBD products stemming from the delisting of hemp as a dangerous drug, and suddenly you have a much more robust marketplace than the one relying on cannabis smokers. When Martha Stewart is offering CBD products, you know something has changed.
What hasn’t changed? The need to distinguish your products from the masses. One way to do that is to employ technology that makes your products more effective than others, increasing the likelihood of satisfied and repeat customers. Ovation Science Inc. (CSE:OVAT) (OTCQB:OVATF) is a company that has done the heavy lifting when it comes to topical and transdermal products with its patented Invisicare® cannabinoid delivery system. Ovation has researched, formulated, and tested over 30 products to date, all of which feature the enhanced deliverability and effectiveness of its Invisicare® technology.
Ovation Works With Licensees, Multi-State Operators
Ovation Science runs its own online sales operations, with Invibe MD targeting the health and wellness sector and ARLO CBD Beauty targeting the beauty and skincare market. Beyond those sites, however, the bulk of the company’s business model consists of partnerships with established operators in the US and Canada. Rather than trying to set up shop in various states and provinces, Ovation offers its Invisicare® technology, and the resulting products, to companies that have already navigated the various regulatory environments across the continent.
The arrangements can take different forms. With its Nevada licensee, for instance, Ovation provides the Invisicare® polymer technology, the product formulations, and the accompanying intellectual property protection. The licensee takes care of product manufacturing and distribution. Other licensees may do the same, or they may choose to employ Ovation’s R&D capabilities to create entirely new products utilizing Invisicare®. Either way, Ovation has the infrastructure, the expertise, and the history to get products into the market quickly for its partners.
Ovation’s technology is scalable to fit whatever the licensee’s requirements and capabilities may be. The company makes it as easy as possible for its partners to create new lines of widely-appealing cannabis-derived products, improve existing product lines, or simply market Ovation’s existing products under their own brand.
The key for Ovation’s exclusive partners is the performance of the product, and the protection of knowing nobody else can make those products in a particular market. The performance is really impressive. The company tested its topical (ingredients to be delivered ON the skin) formulations against a number of leading CBD topicals. The results were staggering, with Invisicare® products demonstrating a 40% active ingredient release rate over a two hour period compared to an average of 3% for the other creams tested. Results were similar for transdermal (ingredients to be delivered THROUGH the skin) formulas, with Invisicare® providing an 80% penetration rate after six hours compared to 10% to 25% for the other products.
Ovation Science is Worth a Look
Whether you are a cannabis retailer looking for a competitive advantage in the booming cannabis-derived products space, or an investor looking for credible and compelling cannabis companies in the public markets, Ovation Science may be worth the time to investigate. The company brings 20 years of patent-protected scientific research and development to a product space that previously has been long on claims and short on proof. It’s a young industry with loads of upside for innovators such as Ovation Science.
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.